Curis’ renaissance continues

In December, six patients’ worth of data boosted Curis’ stock more than fivefold. Yesterday, results in another three patients added 66% to the company’s market cap and raised hopes that the group could have a viable project in the oral Irak-4 inhibitor CA-4948.